Literature DB >> 20968138

Radiotherapy in the treatment of primary osteosarcoma--a single center experience.

Susanne Oertel1, Claudia Blattmann, Stefan Rieken, Alexandra Jensen, Stephanie E Combs, Peter E Huber, Mark Bischof, Andreas Kulozik, Jürgen Debus, Daniela Schulz-Ertner.   

Abstract

PURPOSE: To analyze our experiences concerning radiation treatment in patients with osteosarcoma.
MATERIALS AND METHODS: Since 1981, 40 patients with osteosarcoma have undergone radiotherapy in Heidelberg; 3 of them were immediately lost to follow-up. Twenty patients with metastases were treated palliatively and 17 patients were treated with a curative intent.
RESULTS: Interestingly, 14 of the 17 patients treated with a curative intent were referred to our clinic during the last 8 years, whereas the number of patients referred for palliation decreased. The mean dose applied for palliation was 47 Gy (range, 26 Gy to > 70 GyE), for cure was 59 Gy (range, 45 Gy to > 70 GyE). Local control until death could be achieved in 15 of the 20 palliatively treated patients, with a mean survival of 7 months after radiation. Five patients experienced local failure with symptom recurrence, and 3 of them had received doses > 60 Gy. At last follow-up, 3 of the 17 curatively treated patients had experienced local recurrence. Median follow-up was 32 months (range, 3-144). Estimated 5-year overall survival and local control rates were 38% and 68%, respectively. Local disease-free survival was shorter in patients treated for recurrent, inoperable or incompletely resected tumors and doses below 60 Gy.
CONCLUSIONS: With adequate doses, long-term local control is possible even in inoperable or incompletely resected tumors. Improvements of systemic therapy and modern radiation techniques have begun to bring the possibly curative role of radiation treatment back to the fore. However, in disseminated tumors, even doses beyond 60 Gy do not guarantee local control, suggesting an extremely low radiosensitivity of certain kinds of osteosarcoma.

Entities:  

Mesh:

Year:  2010        PMID: 20968138     DOI: 10.1177/030089161009600411

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  16 in total

1.  Baicalein induces human osteosarcoma cell line MG-63 apoptosis via ROS-induced BNIP3 expression.

Authors:  Fangfan Ye; Honghan Wang; Lusi Zhang; Yongyi Zou; Hailong Han; Jia Huang
Journal:  Tumour Biol       Date:  2015-01-25

2.  HO-3867 Induces Apoptosis via the JNK Signaling Pathway in Human Osteosarcoma Cells.

Authors:  Peace Wun-Ang Lu; Chia-Hsuan Chou; Jia-Sin Yang; Yi-Hsien Hsieh; Meng-Ying Tsai; Ko-Hsiu Lu; Shun-Fa Yang
Journal:  Pharmaceutics       Date:  2022-06-13       Impact factor: 6.525

3.  Effect of RAB31 silencing on osteosarcoma cell proliferation and migration through the Hedgehog signaling pathway.

Authors:  Qiong Yu; Dong Li; Dan Wang; Chun-Mei Hu; Yan Sun; Yan Tang; Guang Shi
Journal:  J Bone Miner Metab       Date:  2018-11-23       Impact factor: 2.626

4.  Celastrol induces apoptosis of human osteosarcoma cells via the mitochondrial apoptotic pathway.

Authors:  Xiaolong Yu; Xin Zhou; Changlin Fu; Qiang Wang; Tao Nie; Fan Zou; Runsheng Guo; Hucheng Liu; Bin Zhang; Min Dai
Journal:  Oncol Rep       Date:  2015-07-13       Impact factor: 3.906

Review 5.  Osteosarcoma in Korean children and adolescents.

Authors:  Jun Ah Lee
Journal:  Korean J Pediatr       Date:  2015-04-22

Review 6.  Review of Osteosarcoma and Current Management.

Authors:  Ryan A Durfee; Maryam Mohammed; Hue H Luu
Journal:  Rheumatol Ther       Date:  2016-10-19

7.  Emodin Impairs Radioresistance of Human Osteosarcoma Cells by Suppressing Sonic Hedgehog Signaling.

Authors:  Wei Qu; Yufei Wang; Qining Wu; Dingjun Hao; Dichen Li
Journal:  Med Sci Monit       Date:  2017-12-05

Review 8.  Radiopharmaceutical therapy in cancer: clinical advances and challenges.

Authors:  George Sgouros; Lisa Bodei; Michael R McDevitt; Jessie R Nedrow
Journal:  Nat Rev Drug Discov       Date:  2020-07-29       Impact factor: 84.694

9.  GO-Y078, a Curcumin Analog, Induces Both Apoptotic Pathways in Human Osteosarcoma Cells via Activation of JNK and p38 Signaling.

Authors:  Peace Wun-Ang Lu; Renn-Chia Lin; Jia-Sin Yang; Eric Wun-Hao Lu; Yi-Hsien Hsieh; Meng-Ying Tsai; Ko-Hsiu Lu; Shun-Fa Yang
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-24

10.  Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways.

Authors:  Hsin-Lin Cheng; Chiao-Wen Lin; Jia-Sin Yang; Ming-Ju Hsieh; Shun-Fa Yang; Ko-Hsiu Lu
Journal:  Oncotarget       Date:  2016-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.